We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Edwards Lifesciences Corporation (EW) is a leading medical devices business with stocks listed in the US. It opened the day at US$116.85 after a previous close of US$120.69. During the day the price has varied from a low of USD117.1 to a high of USD119.65. The latest price was USD119.42 (25 minute delay). Edwards Lifesciences Corporation is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Edwards Lifesciences Corporation
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Edwards Lifesciences Corporation. Find the share by name or ticker symbol: EW. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Edwards Lifesciences Corporation reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$120.69, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Edwards Lifesciences Corporation, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Edwards Lifesciences Corporation. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Edwards Lifesciences Corporation key stats
- Compare share trading platforms
- Is Edwards Lifesciences Corporation stock a buy or sell?
- Edwards Lifesciences Corporation performance over time
- Can I short Edwards Lifesciences Corporation shares?
- Is Edwards Lifesciences Corporation suitable for ethical investing?
- Are Edwards Lifesciences Corporation shares over-valued?
- Edwards Lifesciences Corporation's financials
- How volatile are Edwards Lifesciences Corporation shares?
- Does Edwards Lifesciences Corporation pay a dividend?
- Have Edwards Lifesciences Corporation shares ever split?
- Other common questions
Edwards Lifesciences Corporation stock price (NYSE:EW)Use our graph to track the performance of EW stocks over time.
Edwards Lifesciences Corporation shares at a glance
|52-week range||US$70.92 - US$123.27|
|50-day moving average||US$117.1803|
|200-day moving average||US$103.37|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$2.304|
Where to buy Edwards Lifesciences Corporation stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Edwards Lifesciences Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Edwards Lifesciences Corporation shares?Before you consider Edwards Lifesciences Corporation, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Edwards Lifesciences Corporation price performance over time
|1 week (2021-10-04)||12.27%|
|1 month (2021-09-15)||-1.32%|
|3 months (2021-07-15)||12.30%|
|6 months (2021-04-15)||35.70%|
|1 year (2020-10-15)||39.97%|
|2 years (2019-10-15)||56.70%|
|3 years (2018-10-15)||152.67%|
|5 years (2016-10-14)||208.84%|
Stocks similar to Edwards Lifesciences Corporation
Is Edwards Lifesciences Corporation under- or over-valued?
Valuing Edwards Lifesciences Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences Corporation's P/E ratio
Edwards Lifesciences Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Edwards Lifesciences Corporation shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences Corporation's PEG ratio
Edwards Lifesciences Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3545. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences Corporation's EBITDA
Edwards Lifesciences Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$1.7 billion (£1.2 billion).
The EBITDA is a measure of a Edwards Lifesciences Corporation's overall financial performance and is widely used to measure a its profitability.
Edwards Lifesciences Corporation financials
|Revenue TTM||US$4.9 billion|
|Operating margin TTM||31.38%|
|Gross profit TTM||US$3.3 billion|
|Return on assets TTM||13.71%|
|Return on equity TTM||32.6%|
|Market capitalisation||US$67.8 billion|
TTM: trailing 12 months
Shorting Edwards Lifesciences Corporation shares
There are currently 5.9 million Edwards Lifesciences Corporation shares held short by investors – that's known as Edwards Lifesciences Corporation's "short interest". This figure is 1.3% down from 6.0 million last month.
There are a few different ways that this level of interest in shorting Edwards Lifesciences Corporation shares can be evaluated.
Edwards Lifesciences Corporation's "short interest ratio" (SIR)
Edwards Lifesciences Corporation's "short interest ratio" (SIR) is the quantity of Edwards Lifesciences Corporation shares currently shorted divided by the average quantity of Edwards Lifesciences Corporation shares traded daily (recently around 1.8 million). Edwards Lifesciences Corporation's SIR currently stands at 3.27. In other words for every 100,000 Edwards Lifesciences Corporation shares traded daily on the market, roughly 3270 shares are currently held short.
However Edwards Lifesciences Corporation's short interest can also be evaluated against the total number of Edwards Lifesciences Corporation shares, or, against the total number of tradable Edwards Lifesciences Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edwards Lifesciences Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Edwards Lifesciences Corporation shares in existence, roughly 10 shares are currently held short) or 0.0096% of the tradable shares (for every 100,000 tradable Edwards Lifesciences Corporation shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edwards Lifesciences Corporation.
Find out more about how you can short Edwards Lifesciences Corporation stock.
Edwards Lifesciences Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Edwards Lifesciences Corporation's total ESG risk score
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences Corporation's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Edwards Lifesciences Corporation's environmental score
Environmental score: 4.78/100
Edwards Lifesciences Corporation's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Edwards Lifesciences Corporation's social score
Social score: 13.43/100
Edwards Lifesciences Corporation's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Edwards Lifesciences Corporation's governance score
Governance score: 10.96/100
Edwards Lifesciences Corporation's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Edwards Lifesciences Corporation's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences Corporation has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||21.68|
|Total ESG percentile||24.1|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
Edwards Lifesciences Corporation share dividends
We're not expecting Edwards Lifesciences Corporation to pay a dividend over the next 12 months.
Have Edwards Lifesciences Corporation's shares ever split?
Edwards Lifesciences Corporation's shares were split on a 3:1 basis on 31 May 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences Corporation shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences Corporation shares which in turn could have impacted Edwards Lifesciences Corporation's share price.
Edwards Lifesciences Corporation share price volatility
Over the last 12 months, Edwards Lifesciences Corporation's shares have ranged in value from as little as US$70.92 up to US$123.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences Corporation's is 1.0751. This would suggest that Edwards Lifesciences Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation in the news
Wedgewood Partners Third Quarter 2021 Client Letter
EW December 17th Options Begin Trading
Boston Scientific (BSX) Inks New Deal to Buy Baylis Medical
Frequently asked questions
More guides on Finder
Why is the a2 Milk (A2M) share price on a high?
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Why has the Bank of Queensland (BOQ) share price stumbled?
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
How to invest in the Tissue Repair IPO
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
How to buy Illuvium (ILV) in Australia
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
What is weighing down the Westpac share price today?
Westpac shares are up 43% over the past 12 months.
16 stocks to watch following Sydney’s “freedom day”
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Why is the IAG share price on a high today?
Shares in the insurer are up just 10% in the last 12 months.
How to invest in the Nimy Resources IPO
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
Why the EML Payments share price is plunging today
The payment services company’s shares are up 16% in the last year.
How to invest in the Parabellum Resources IPO
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
Ask an Expert